[1] 王宇光,高月.中草药对细胞色素P-450酶调控研究进展[J]. 中草药,2003,34(5):477-479. [2] Wen X, Wang JS, Backman JT,et al.Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9[J].Drug Metab Dispos,2001,29(11): 1359-1361. [3] Wang JS, Neuvonen M, Wen X, et al.Gemfibrozil inhibits CYP2C8-mediated cerivastatin metabolism in human liver microsomes[J]. Drug Metab Dispos, 2002,30(12): 1352-1356. [4] Deng LJ, Wang F, Li HD .Effect of gemfibrozil on the pharmacokinetics of pioglitazone[J]. Eur J Clin Pharmacol,2005,61(11): 831-836. [5] Jaakkola T, Backman JT, Neuvonen M,et al.Effects of gemfibrozil, itraconazole,and their combination on the pharmacokinetics of pioglitazone[J]. Clin Pharmacol Ther,2005,77(5):404-414. [6] Gan J, Chen W, Shen H, et al. Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism[J]. Br J Clin Pharmacol,2010 ,70(6):870-880. [7] Niemi M, Backman JT, Granfors M, et al. Gemfibrozil considerably increases the plasma concentrations of rosiglitazone[J]. Diabetologia,2003, 46(10):1319-1323. [8] Laitila J, Neuvonen PJ, Backman JT. Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors[J]. Basic Clin Pharmacol Toxicol,2006,99(1):44-51. [9] Baldwin SJ, Clarke SE, Chenery RJ.Characterization of the cytochrome P450 enzymes involved in the in vitro metabolism of rosiglitazone[J]. Br J Clin Pharmacol,1999,48:424-432. [10]Wen X,Wang JS, Backman JT, KivistKT, Neuvonen PJ.Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9[J]. Drug Metab Dispos,2001,29(11):1359-1361. [11]Prueksaritanont T, Richards KM, Qiu Y.Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes[J]. Pharm Res, 2005,22(1):71-78. [12]Bidstrup TB, Bjrnsdottir I, Thomsen MS, et al.CYP2C8 and CYP3A4 are the principle enzymes involved in the in vitro biotransformation of the insulin secretagogue repaglinide[J]. Br J Clin Pharmacol,2003,56(3): 305-314. [13]Weaver ML, Orwig BA, Rodriguez LC, et al. Pharmacokinetics and metabolism of nateglinide in humans[J]. Drug Metab Dispos, 2001, 29(4 Pt 1): 415-421. [14]Tornio A, Niemi M, Neuvonen M, et al.The effect of gemfibrozil on repaglinide pharmacokinetics persists for at least 12 h after the dose: evidence for mechanism-based inhibition of CYP2C8 in vivo[J]. Clin Pharmacol Ther,2008, 84(3):403-411. [15]Niemi M, Backman JT, Neuvonen M, et al. Effects of gemfibrozil, itraconazole, and their combination on the pharmacokinetics and pharmacodynamics of repaglinide: potentially hazardous interaction between gemfibrozil and repaglinide[J]. Diabetologia,2003,46(3):347-351. [16]Niemi M, Backman JT, Juntti-Patinen L,et al.Coadministration of gemfibrozil and itraconazole has only a minor effect on the pharmacokinetics of the CYP2C9 and CYP3A4 substrate nateglinide[J].Br J Clin Pharmacol,2005,60(2):208-217. [17]Backman JT, Honkalammi J, Neuvonen M,et al. CYP2C8 Activity recovers within 96 hours after gemfibrozil dosing: estimation of CYP2C8 half-life using repaglinide as an in vivo probe[J].Drug Metab Dispos,2009,37(12):2359-2366. [18]Niemi M, Cascorbi I, Timm R,et al. Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes[J]. Clin Pharmacol Ther, 2002,72(3):326-332. [19]Niemi M, Neuvonen PJ, Kivist KT. Effect of gemfibrozil on the pharmacokinetics and pharmacodynamics of glimepiride[J]. Clin Pharmacol Ther,2001, 70(5):439-445. [20]Ogilvie BW, Zhang D, Li W, et al. Glucuronidation converts gemfibrozil to a potent, metabolism-dependent inhibitor of CYP2C8: implications for drug-drug interactions[J]. Drug Metab Dispos,2006,34(1):191-197. [21]Kalliokoski A, Backman JT, Kurkinen KJ, et al.Effects of gemfibrozil and atorvastatin on the pharmacokinetics of repaglinide in relation to SLCO1B1 polymorphism[J]. Clin Pharmacol Ther,2008, 84(4):488-496. [22]Gan J, Chen W, Shen H, et al.Repaglinide-gemfibrozil drug interaction: inhibition of repaglinide glucuronidation as a potential additional contributing mechanism[J]. Br J Clin Pharmacol, 2010,70(6):870-880. [23]吴剑琴,杨二杨,官兴荣.吉非罗齐对2 型糖尿病血脂及血糖代谢的影响[J].实用医学杂志,2000,16(5):410-411. [24]黄燕南.吉非罗齐治疗糖尿病脂代谢异常40 例临床分析[J].现代中西医结合杂志,2005 , 14(3):319. [25]漆泓,孙明,周宏研.吉非罗齐对代谢综合征血脂及胰岛素抵抗的影响[J].中国现代医学杂志,2004,14(17):50-53. |